Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 171

The DOI matches its Crossref record.

Immunomodulatory action of intravenous immunoglobulin

Open access
Sewell, W. A. C., Jolles, S. · 2002 · Immunology

Abstract

Intravenous immunoglobulin (IVIg) is a blood product prepared from the serum of between 1000 and 15 000 donors per batch. It is the treatment of choice for patients with antibody deficiencies. In this indication, IVIg is used at a 'replacement dose' of 200–400 mg/kg body weight, given approximately 3-weekly. In contrast, 'high-dose' IVIg (hdIVIg), given most frequently at 2 g/kg/month, is used as an 'immunomodulatory' agent in an increasing number of immune and inflammatory disorders. Initial use of hdIVIg was for idiopathic thrombocytopenic purpura (ITP) in children.1 Despite a lack of double-blind, randomized, placebo-controlled trials, many other conditions are managed with hdIVIg, including numerous haematological, rheumatological, neurological and dermatological disorders.2 In this article, we review the current understanding and recent developments in the immunomodulatory mechanisms of action of hdIVIg. IVIg may, for the purposes of clarity, be considered to have four separate mechanistic components: (1) actions mediated by the variable regions F(ab′)2, (2) actions of Fc on a range of Fc receptors (FcR), (3) actions mediated by complement binding within the Fc fragment, and (4) immunomodulatory substances other than antibody in the IVIg preparations (Fig. 1). It is likely that these components act concurrently, however, different mechanisms may be important in different settings. We will address the mechanisms under these broad headings although in some cases more than one mechanism is operative or our understanding does not allow accurate categorization. Immunomodulatory actions of intravenous immunoglobulin. Intravenous immunoglobulin (IVIg) may for the purposes of understanding be thought of as four separate components: (1) actions mediated by the variable regions F(ab′)2, (2) actions of Fc on a range of Fc receptors (FcR), (3) actions mediated by complement binding within the Fc fragment, and (4) immunomodulatory substances other than antibody in the IVIg preparations. It should be remembered that not all of the potential mechanisms of action fit perfectly into the groupings and that several mechanisms may act concurrently. (TCR, T-cell receptor; ADCC, antibody-dependent cellular cytotoxicity). IVIg has been shown to have a considerable inhibitory effect on mitogen-induced T-cell proliferation in vitro.3 This effect has been shown for intact immunoglobulin G (IgG), with less evidence for a role for Fc fragment.4 Single-donor preparations of IVIg inhibited proliferation more than commercial multiple-donor preparations, but there was no difference between standard IVIg preparations and cytomegalovirus hyperimmune globulin.4 Both antigen-dependent and antigen-independent responses are inhibited by IVIg in a dose-dependent manner.5 T-cell proliferation in response to anti-CD3 or tetanus toxoid was shown to be inhibited by IVIg in a dose-dependent manner over a range of IgG concentrations (0–10 mg/ml).6 The inhibition was reversible by exogenous interleukin-2 (IL-2) and the authors concluded that the effects were a result of interference with cytokine-mediated T-cell proliferation. Both pooled normal human immunoglobulin, and single donor immunoglobulin were shown to reduce pokeweed mitogen (PWM) -induced plaque-forming cell formation following 300 mg/kg infusions into patients with common variable immunodeficiency.7 This effect was short-lived, and sera collected >24 hr post-infusion no longer inhibited cell proliferation. The suppressive effects of IVIg when used at replacement dose (100–200 mg/kg) were demonstrated in antibody-deficient children.8 In this study, the effects of the children's sera on the immunoglobulin-producing activity of PWM-stimulated normal lymphocytes was assessed. Even this low-dose IVIg was shown to enhance the suppressive activity of the patient's lymphocytes, an effect that was reversed on cessation of IVIg therapy. IVIg has been shown to suppress the proliferation of antigen-specific T cells without inducing apoptosis, the cells remaining refractory to induction of apoptosis by CD95 ligation.9 Interestingly, Bcl-2 expression was not affected by IVIg in this study. In a further in vitro study10 a dual effect by IVIg was found. The incidence of apoptosis was elevated in activated Ki-67 and CD95-positive peripheral blood mononuclear cells (PBMC), whereas it was lower in small, non-activated cells. The cells that survived exhibited a striking increase in the expression of p21/WAF-1, suggesting G1 arrest. A concomitant up-regulation of Bcl-2 was also observed following exposure to IVIg, resulting in long-term survival. Additional studies have confirmed that IVIg causes the arrest of cells at the G0/G1 phase of the cell cycle, and inhibits cells from entering S-phase.11 IVIg has been demonstrated to induce apoptosis in leukaemic lymphocytes and monocytes as well as normal tonsillar B cells, an effect mediated at least in part by anti-CD95 antibodies present within the IVIg prepa

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1046/j.1365-2567.2002.01545.x

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 171

Metadata

Authors
Sewell, W. A. C., & Jolles, S.
Venue
Immunology
Publisher
Wiley
Published
2002-12
Volume
107
Issue
4
Pages
387-393
ISSN
  • 0019-2805 (ISSN-L)
  • 1365-2567
OpenAlex
W2056820060
Cited by
171
References
0
FWCI
9.41
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Immunomodulatory action of intravenous immunoglobulin. https://app.cochat.ai/papers/10.1046/j.1365-2567.2002.01545.x
The paper
Sewell, W. A. C., & Jolles, S. (2002). Immunomodulatory action of intravenous immunoglobulin. Immunology. https://doi.org/10.1046/j.1365-2567.2002.01545.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.